文献速递老年精神精神分裂症与精神病性障碍会诊联络精神医学

阿尔茨海默病中的精神病性症状与疾病相关生物标志物升高

Psychosis in Alzheimer Disease and Elevations in Disease-Relevant Biomarkers.
PubMed 文献 · JAMA Psychiatry · 2024-01-01

该队列研究基于阿尔茨海默病神经影像学倡议(ADNI)纵向数据,分析752例阿尔茨海默病(AD)患者及424名认知功能正常者血浆p-tau181与NfL水平与精神病性症状出现的关系。结果显示,随访期间新发精神病性症状的AD患者血浆p-tau181水平呈上升趋势,而基线即有精神病性症状者呈下降趋势,两者斜率差异显著;任何时间出现精神病性症状者NfL水平高于从未出现者。作者认为精神病性症状出现与血浆p-tau181升高相关,提示其作为AD神经精神疾病生物标志物的潜在效用。

要点

  • 随访中新发精神病性症状的AD患者血浆p-tau181水平较基线即有症状者呈上升趋势。
  • 新发与基线精神病性症状两组间p-tau181变化斜率差异显著(F5,746=86.76,P<.0001)。
  • 任何时间出现精神病性症状者NfL水平高于从未出现者。

核心结论

  • 作者认为AD中精神病性症状的出现与血浆p-tau181水平升高相关,提示血浆p-tau181作为AD神经精神疾病生物标志物的潜在效用,可能对预测和治疗反应策略有启示。

研究设计与样本

  • 本研究为队列研究,使用阿尔茨海默病神经影像学倡议(ADNI)的纵向数据。
  • 基线分析比较轻度认知障碍(MCI)和AD患者(伴精神病性症状[AD+P]与不伴[AD-P])及认知功能正常(CU)参与者。
  • 纵向分析将MCI和AD患者分为基线即有精神病性症状者(AD+P baseline)和基线无精神病性症状但研究期间新发者(AD+P incident)。
  • 研究数据于2023年6月至11月间分析。
  • 队列包括752例AD患者(平均[SD]年龄74.2[7.7]岁;434例男性[57.7%])和424名CU参与者(平均[SD]年龄75.4[6.6]岁;222例女性[52.4%])。

主要发现

  • AD+P incident组与AD+P baseline组p-tau181变化平均斜率差异显著(F5,746=86.76,P<.0001)。
  • 仅比较经正电子发射断层扫描确定的淀粉样蛋白β阳性(Aβ+)个体时,两组斜率差异亦显著(F5,455=84.60,P<.001)。
  • 任何时间出现精神病性症状的患者NfL水平高于从未出现精神病性症状者。
  • 血浆p-tau181和NfL定量检测随访至48个月,同时通过神经精神科问卷(NPI)评估妄想和幻觉的有无。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The emergence of psychotic symptoms in Alzheimer disease (AD) is associated with accelerated cognitive and functional decline that may be related to disease pathology. OBJECTIVE: To investigate the longitudinal dynamics of plasma tau phosphorylated at threonine 181 (p-tau181) and neurofilament light chain protein (NfL) levels in association with the emergence of psychotic symptoms (delusions and hallucinations) in the context of AD. DESIGN, SETTING, AND PARTICIPANTS: This cohort study used longitudinal data from the Alzheimer Disease Neuroimaging Initiative (ADNI). Baseline analyses compared patients with mild cognitive impairment (MCI) and AD (both with psychosis [AD+P] and without psychosis [AD-P]) and participants who were cognitively unimpaired (CU). For the longitudinal analysis, participants with MCI and AD were subdivided into patients with evidence of psychosis at baseline (AD+P baseline) and patients free of psychosis at baseline who showed incidence of psychosis over the course of the study (AD+P incident). Study data were analyzed between June and November 2023. EXPOSURES: Plasma p-tau181 and NfL measures in individuals with MCI and AD, both with and without psychosis. MAIN OUTCOMES AND MEASURES: Plasma p-tau181 and NfL quantifications up to 48 months and concurrent assessments of presence or absence of delusions and hallucinations via the Neuropsychiatric Inventory (NPI) questionnaire. RESULTS: The cohort included 752 participants with AD (mean [SD] age, 74.2 [7.7] years; 434 male [57.7%]). A total of 424 CU participants had a mean (SD) age of 75.4 (6.6) years of whom 222 were female (52.4%). In the longitudinal analysis of p-tau181 trajectories of the AD+P group, the group of patients who showed incidence of psychosis over the course of follow-up (AD+P incident) demonstrated an associated increase in plasma p-tau181 levels compared with the group of patients who had psychosis at baseline (AD+P baseline) and showed an associated decrease in plasma p-tau181 levels (F4, 117 = 3.24; P = .01). The mean slope of p-tau181 change was significantly different in AD+P incident and AD+P baseline groups (F5,746 = 86.76, P < .0001) and when only individuals with amyloid-β positivity (Aβ+), which was determined using positron emission tomography, were compared (F5,455 = 84.60, P < .001). Patients who experienced psychosis at any time had increased levels of NfL relative to those who never experienced psychosis. CONCLUSIONS AND RELEVANCE: Results of this cohort study suggest that the emergence of psychosis in AD was associated with elevations in plasma levels of p-tau181, highlighting the potential utility of plasma p-tau181 as a biomarker of neuropsychiatric illness in AD, which could have implications for predictive and treatment response strategies.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Gomar JJ, Koppel J. Psychosis in Alzheimer Disease and Elevations in Disease-Relevant Biomarkers. JAMA Psychiatry. 2024. PMID: 38922609. doi:10.1001/jamapsychiatry.2024.1389

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。